Diagnosis, Risk Stratification, And Management Of Pulmonary Hypertension Of Sickle Cell Disease.
Key Points
Key Points
Observational studies have consistently shown that increased tricuspid regurgitant jet velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro–brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension measured by right heart catheterization are all independent risk factors for mortality in adults.
To reduce the variability and to improve the quality of care that patients with SCD receive, the ATS developed clinical practice guidelines to advise hematologists, pulmonologists, cardiologists, pediatricians, and internists about how to identify and manage patients with SCD who are at increased risk for mortality.
Diagnosis
...gnosis
...k stratification guides clinical decision maki...
...k for mortality is defined as a TRV ≥2.5...
...ample Questions for Evaluation of Dyspn...
...roposed Algorithm for Evaluation of Pulm...
.... Echocardiogram of a Patient with Pulmonary...
Treatment
...eatment
For patients with SCD who have an incr...
...s with SCD who have an increased risk for...
...patients with SCD who have RHC-co...
...ients with SCD who have elevated TRV alo...
...or most patients with SCD who have RHC-confirm...
...r select patients with SCD who have...
...patients with SCD who have RHC-con...
...e 2. MedicationsHaving trouble viewing table? Expa...